Israeli versus US seed pricing: what the published data shows, and what it does not

The published numbers

The published figures compare round sizes more readily than valuations, and on round size the two markets are not what the labels suggest. A US seed round had a median deal value of $3.0 million in the first half of 2026 in the PitchBook-NVCA Venture Monitor, down from $3.5 million in 2025. Tracked Israeli seed deals in the same half had a median of $10.1 million, or $8.0 million once the largest handful are set aside.

IVC's quarterly review, which groups pre-Seed through Series A as "early rounds", shows the Israeli median rising from $10.5 million in 2025 to $14 million in the first half of 2026, with the caveat that the market is concentrating capital in fewer companies: fewer startups are raising, and the ones that do raise more. At the other end, IVC's pre-Seed median has been flat at $0.2 million since 2023. On the US side, the same PitchBook report notes that seed is the only series whose median deal value fell in the first half of 2026, while median pre-money valuations at every series have pushed past their 2021 highs.

What is not published, in any of the sources this site relies on, is a seed pre-money valuation median for Israel. Carta reports US seed medians (its Q1 2026 summary cites a $24 million median post-money on a $4.1 million round), but there is no equivalent Israeli series in the public IVC or Startup Nation Central reports. The data note tracks both series and shows them as pending until a sourced figure exists.

Why the gap exists

The round-size gap exists because Israeli companies raise their first institutional round later in the company's life. A typical Israeli seed company has a product, early customers and sometimes revenue; the round that carries the "seed" label funds go-to-market, and it is sized accordingly. A US seed company at the same label is often pre-product, funding the build.

That difference has structural causes. Israeli founders leave the army and university with years of applied technical work behind them, often with a co-founding team that has already built together, so the product phase is short and self-funded or angel-funded. The domestic market is small, so the company sells abroad from the first customer, which pushes the go-to-market spend into the seed round. And the pool of Israeli seed investors is thinner than the US pool, so a company that has reached the seed stage is one that has already cleared a higher bar.

The valuation question is separate, and it is where the thesis lives. The argument is that Israeli seed rounds price below US rounds for a company of comparable maturity, because the local investor base is smaller, because US coastal funds rarely lead Israeli seed rounds, and because the founders benchmark against local comparables. That argument is consistent with what practitioners on both sides report, but it is not yet a published series, and this guide does not claim a number it cannot cite.

Where the gap is narrowing

The gap is narrowing at the top of the market and at the pre-seed end. IVC records early-round medians at historic highs in the first half of 2026, driven by larger rounds into fewer companies and by the surge in defense, space and quantum funding, and Startup Nation Central reports pre-seed round sizes and valuation caps rising year over year. Israeli founders raising in cyber, defense and AI infrastructure in 2026 are increasingly priced against US comparables.

Two forces push the other way. The market's own concentration means the median company outside the top decile is raising less, later, on local terms, which is exactly the company a seed fund with relationships can reach. And the pre-seed stage has stayed stagnant, with IVC's median flat at $0.2 million since 2023 and the pool of individual backers contracting, so the entry point before the institutional seed is, if anything, cheaper than it was.

The practical reading is that "buy in Tel Aviv" is a statement about access to the median company at the seed stage, not about a market-wide discount that anyone can capture by wiring money into the hot rounds.

What it means for entry price

For a fund, the entry price is the valuation at which its first check goes in, and the spread is that valuation set against the US valuation of a company with the same product, team and traction. On the round-size evidence alone, an Israeli seed company is a later, more de-risked company than the US label implies, which means the relevant US comparable is often a Series A, not a seed.

If the valuation evidence, once published, shows Israeli seed rounds pricing at or near US seed valuations while the companies look like US Series A companies, the spread is the difference between those two US price points, captured at entry. If it shows Israeli rounds priced at US Series A levels, the spread is smaller than the thesis assumes and the fund's edge is selection and access rather than price. Olivent's position is that the first reading is the right one for the median company outside the top decile; the data note is where that claim will be tested against numbers as they are published.

Either way, the arithmetic of a seed fund is set by the outliers, and the exit side of the spread, US acquirers and US public markets, is where Israeli-founded companies have historically realised value. The Fund I terms and the thesis describe how Olivent is built around that.